Another study through the afatinib compassionate use program examined 100 NSCLC patients with BM and/or leptomeningeal disease who had progressed on platinum chemotherapy and a first-generation EGFR TKI, 74% of whom had a documented EGFR mutation (59). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.